Special Issue "Using State-Of-The-Art Proteomics to Understand Infectious Diseases. Novel Clinical Diagnostics, Biomarkers and Drug Targets"

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Infectious Disease".

Deadline for manuscript submissions: 31 October 2020.

Special Issue Editors

Dr. Berta Cillero-Pastor
Guest Editor
The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands
Interests: Mass spectrometry imaging (MSI) is a label free technique used to visualize the spatial distribution of biomolecules such as peptides, proteins, lipids or other organic compounds by their molecular masses. In my current work, I develop and employ mass spectrometry imaging and proteomic methodologies to increase our understanding on musculoskeletal and inflammatory pathologies. My aim is to describe future diagnostic or prognostic biomarkers of these diseases
Dr. Monica Cartelle Gestal
Guest Editor
Department of Microbiology and Immunology, Louisiana State University - Health Center, Shreveport, Louisiana, USA
Interests: One of the major hurdles to the success of bacterial pathogens is the host immune response. It is known that bacteria are able to sense and respond to the host environment using different mechanisms. In my current work, using the robust Bordetella spp. murine model a natural host-pathogen infection, I am able to exploit the tools of mouse immunology and forward genetic approaches to test the principles of bacterial pathogenesis and inter-kingdom communication. My goal is to create novel vaccines and therapies to treat multi-drug-resistant bacteria based on the understanding of the mechanisms that bacteria utilize to manipulate host immune response
Special Issues and Collections in MDPI journals
Dr. Eva Torres-Sangiao
Guest Editor
Foundation of The Health Research Institute (FIDIS), University Hospital Complex (CHUS), of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Division of Infection Medicine, Department of Clinical Sciences, Lund University, 221 84 Lund, Sweden
Interests: Understanding the mechanisms of the interactions between host and pathogen, their binding and signalling effects, is the main step to develop clinical relevant insights and new immunotherapies to overcome the infectious diseases. Systems biology targets networks, cells, organs and organisms by integrating experimental data with computational and theoretical approaches comprising different disciplines such as, immunoproteomics, in order to obtain a quantitative understanding of complex biological systems in terms of their components and interactions, as well as predictive models for a better understanding of complex systems. My major research goal is to investigate the dynamics of molecular systems in the cellular environment using proteomic approaches. Secondly, discovering biomarkers for a fast-clinical diagnosis and novel drugs or therapies against infectious diseases
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Infectious diseases continue to be the number one cause of mortality worldwide, and with the exponential increase in antibiotic resistance, we are facing an era in which the WHO expects around 10 million deaths per year by 2050. This situation creates an imperative need for rapid and precise diagnosis, allowing for quick and efficient treatment that can stop the spread of infectious agents. A challenge in medical microbiology is to develop and apply new experimental approaches that allow for the identification of the microbe as well as its susceptibility profile in a time-sensitive manner. A plethora of novel technologies is being adopted in the diagnostics laboratories to augment specificity and sensitivity and decrease morbidity and mortality. Genomics, transcriptomics, proteomics, and metabolomics are new tools applied to an old problem but reveal that the opportunities to apply novel technologies in the diagnostic field are limitless. Faster and more accurate clinical diagnosis helps to improve health and provide targeted therapies that can be tailored to an individual patient and a specific pathogen.

This Special Issue will focus on translational mass spectrometry-based approaches applied to infectious diseases.

Dr. Berta Cillero-Pastor
Dr. Monica Cartelle Gestal
Dr. Eva Torres-Sangiao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Infectious disease
  • Tropical diseases
  • Microbiology diagnosis
  • Mass spectrometry
  • Mass spectrometry imaging
  • Antimicrobial resistance
  • Biomarkers
  • Host-pathogen interactions
  • Antimicrobial and antiviral therapies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessArticle
Fosfomycin, Applying Known Methods and Remedies to A New Era
Diseases 2020, 8(3), 31; https://doi.org/10.3390/diseases8030031 - 07 Aug 2020
The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as [...] Read more.
The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined therapy scheme. However, the assessment of fosfomycin susceptibility in the laboratory presents a great challenge due to the discrepancies found between different methodologies. Thus, our goal was to evaluate fosfomycin susceptibility in a group of 150 Enterobacteriaceae bacterial isolates using agar dilution as the gold standard technique to compare the results with those obtained by disk diffusion. We found a fosfomycin susceptibility of 79.3% in general terms. By comparing both methodologies, we reported a categorical agreement of 96% without Very Major Errors (VMEs) or Major Errors (MEs) and 4% of minor Errors (mEs). Our results suggest that fosfomycin could provide a rational alternative treatment for those patients that are infected by a Multidrug-Resistant (MDR) microorganism that is currently untreatable and that the disk diffusion and classical agar dilution techniques are adequate to assess the resistance profile of CRE to fosfomycin. Full article
Show Figures

Figure 1

Back to TopTop